BioNTech Fills Coffers With Extra $325m Via Series B Financing
Executive Summary
Mainz-based BioNTech raises $325m in an upsized series B round to further advance its individualized immuno-oncology pipeline and manufacturing infrastructure.
You may also be interested in...
BioNTech Bags Bargain With Neon Buy
Neon listed on the NASDAQ at $16 per share 18 months ago. It has now been picked up by the ambitious German biotech for just $2.18 per share, having recently ended its cancer vaccine programs and laid off a quarter of its workforce.
Finance Watch: BioNTech, Vir Launch IPOs But Take US Offerings To Market At A Discount
BioNTech's $150m offering, after a prior large venture capital financing, gives it the third-largest market cap for a newly public drug developer in the US. Also, Innovent raises $300m in Hong Kong offering, Heron leads US follow-ons and Five Prime restructures to save $20m annually.
Venture Funding Deals: July Sees Seven Rounds Of $100m Or More
Century Therapeutics brings in $250m for its cell therapy programs in a series A round, while immunotherapy specialist BioNTech sets a record for series B, raising $350m. Another five firms brought in rounds of $100m or greater...